Clinical Trial

AEWS1221, Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Recruiting participants (Starts Jan. 5, 2015)

Not accepting healthy volunteers

UTSW Principal Investigator: Patrick J Leavey

summary

See protocol/CiRB application

eligibility

See protocol

ParticipateIf you are interested in this clinical trial, please contact AMANDA RICHARDS on the Children’s Health Research Team.Call 214-456-6300 Email